RainMed

RainMed's business model centers on the design, development, and commercialization of devices for the precise diagnosis of coronary conditions. The company generates revenue through the sale of its medical systems and associated disposable components to hospitals and clinics. Its client base consists of healthcare institutions performing cardiac interventions, with products utilized in over 1,000 hospitals across China and expanding into international markets. To facilitate market penetration, RainMed has established strategic partnerships with medical device distribution platforms and collaborates with top medical centers on clinical research.

The company's core product is the Coronary Angiography-Derived Fractional Flow Reserve (caFFR) system. This system provides a non-invasive method to assess the severity of coronary artery stenosis, which is a narrowing of the arteries. Unlike the traditional method that requires an invasive pressure wire and vasodilators, the caFFR system calculates the FFR value using computational fluid dynamics (CFD) applied to standard coronary angiograms. This process involves creating a 3D model from two angiogram images to analyze blood flow and pressure, delivering results in approximately two to three minutes. The key benefits include enhanced safety by avoiding invasive wires, improved efficiency in the cardiac catheterization lab, and wider applicability as it can be used for patients who have contraindications to vasodilator drugs. RainMed also develops the caIMR system for assessing coronary microvascular resistance and the FlashBot, a vascular interventional surgery robot, to further build out its platform of solutions for vascular disease.